Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

IFF

  • Home
  •  
  • IFF



  • Most Read
  • Latest Comments
  • Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments
    Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments
    • News

  • Biome exceeds $7 million sales revenue target for FY23 thanks to its Activated Probiotics range
    Biome exceeds $7 million sales revenue target for FY23 thanks to its Activated Probiotics range
    • News

  • Microba launches gut health test for clinicians, expanding their B2B business
    Microba launches gut health test for clinicians, expanding their B2B business
    • News

  • The key to happiness lies in your gut… No, really, just ask Microba
    The key to happiness lies in your gut... No, really, just ask Microba
    • News

  • New Anatara trial to tackle anxiety, stress and depression with diet supplement
    New Anatara trial to tackle anxiety, stress and depression with diet supplement
    • News

  • Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments
    • News

    Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments

    Precision microbiome company Microba (ASX: MAP) and the US-based F&B company International Flavors & Fragrances (IFF) have entered the second phase of their joint research initiative, aiming to develop novel microbiome-based treatments for various allergies. The collaboration, a strategic move within the bioscience and health sectors, signals a step forward in addressing the need for

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.